Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (98)	4/12/1998 11:51:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

From the GNE 10-K, 3/4/98...... ever wondered who these guys are? I have. Let's keep an eye on them. The Company is a limited partner in the Vector Later-Stage Equity Fund II, L.P. (Vector Fund). The General Partner is Vector Fund Management II, L.L.C., a Delaware limited liability company. The purpose of the Vector Fund is to invest in biotech equity and equity-related securities. Under the terms of the Vector Fund agreement, the Company makes contributions to the capital of the Vector Fund through installments in cash as called by the General Partner. The Company's total commitment to the Vector Fund through September 2003 is $25.0 million, of which $1.0 million was contributed as of December 31, 1997 and another $1.8 million was contributed in January 1998. The Vector Fund will terminate and be dissolved in September 2007.

To: scaram(o)uche who wrote (98)	4/12/1998 11:52:00 AM
From: scaram(o)uche	Respond to of 4974

HAPPY EASTER! (EOM)

To: scaram(o)uche who wrote (98)	4/12/1998 9:11:00 PM
From: Steve Lokness	Respond to of 4974

Rick; I had not read the news release from Nexell, but found it most interesting. What the heck is Nexell doing releasing a news release on FDA findings for CPRO? It would seem to me a continuation of the seemingly incredible attempt to get their product approved without having to go through phase three trials. Who is this news release for - the FDA! It would seem to me that this type of hype is exactly how companies get into shareholder lawsuits. What happens to shareholder value if CPRO wins the lawsuit - and they could - and FDA requires phase three trials? Maybe Baxter business strategy is rubbing off. It has been so long I don't remember what the sales projections were for CPRO, but significant for sure. Who hears the appeal? judge? Rick, I don't know what your last comment refers to. What does "hypericin" mean and which company are you referring to? If you are referring to the joint formed venture that created Nexell and the word is a derivative of the prefix "hype" then I agree. Good Investing. Steve